PROK
Bearish signalScored 2026-08-21 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
ProKidney Corp.
- Nom
- ProKidney Corp.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $480.8M
- Employés
- 231
- PDG
- Bruce Culleton
- Site web
- https://www.prokidney.com
- Marché
- ARDXDMACMAZEMENSTVTXUNCY
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 81 929 titres (~115 538,52 $ US)
- Insiders
- Pereira Brian JG
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$115,539
Avg sell (VWAP, 90d window) $1.41 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-20
- Last synced
-
2026-08-26 03:23:35
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-20 | Pereira Brian JG | Sell · S | 27,052 | $1.42 | $38,411 | Form 4 |
| 2026-08-19 | Pereira Brian JG | Sell · S | 27,051 | $1.44 | $38,972 | Form 4 |
| 2026-08-18 | Pereira Brian JG | Sell · S | 27,826 | $1.37 | $38,155 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-08-21 Drivers: fundamentals. Moteurs : fondamentaux.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 9.13 · operating margin -18478% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -16931.0% | -215689.5% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -16194.7% | -208542.1% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -18477.8% | -241678.9% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -16931.5% | -215701.3% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -16977.8% | -214914.5% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -7725.2% | -80507.9% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -7725.2% | -80507.9% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.130 | 10.931 | 14.943 | 46.419 | 2.215 | |
| Quick Ratio | 9.130 | 10.931 | 14.943 | 46.419 | 2.215 | |
| Solvency Ratio | -1.794 | -1.414 | -1.082 | -8.041 | -3.973 | |
| Cash Ratio | 3.531 | 2.737 | 2.422 | 45.089 | 1.669 | |
| Price To Earnings Ratio | -4.308 | -2.726 | -3.123 | -3.898 | -5.723 | |
| Price To Earnings Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Forward Price To Earnings Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Price To Earnings Diluted Ratio | -4.308 | -2.726 | -3.123 | -3.898 | -5.723 | |
| Price To Earnings Diluted Growth Ratio | 0.267 | -0.311 | 0.046 | -2.248 | -0.005 | |
| Price To Book Ratio | -0.297 | -0.166 | -0.100 | -0.385 | 11.729 | |
| Price To Sales Ratio | 335.982 | 2,177.347 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -2.217 | -1.062 | -0.884 | -5.348 | -5.689 | |
| Price To Operating Cash Flow Ratio | -2.498 | -1.310 | -1.220 | -5.476 | -6.277 | |
| Debt To Assets Ratio | 0.012 | 0.007 | 0.010 | 0.005 | 0.033 | |
| Debt To Equity Ratio | -0.004 | -0.003 | -0.004 | -0.002 | 0.050 | |
| Debt To Capital Ratio | -0.004 | -0.003 | -0.004 | -0.002 | 0.047 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -0.332 | -0.443 | -0.381 | -0.472 | 1.497 | |
| Working Capital Turnover Ratio | 0.003 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -3.907 | -3.489 | -3.597 | -7.090 | -4.085 | |
| Operating Cash Flow Sales Ratio | -134.510 | -1,662.513 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.127 | 1.234 | 1.380 | 1.024 | 1.103 | |
| Debt Service Coverage Ratio | -36,258.250 | -17,543.778 | -10,965.167 | -673.879 | 0.000 | |
| Interest Coverage Ratio | -41,251.750 | -20,408.444 | -12,626.833 | -711.660 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -29.761 | -39.045 | -20.410 | -32.134 | -37.705 | |
| Capital Expenditure Coverage Ratio | -7.905 | -4.282 | -2.634 | -41.760 | -9.688 | |
| Dividend Paid And Capex Coverage Ratio | -7.905 | -4.282 | -2.634 | -41.760 | -9.688 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.986 | -1.764 | -1.537 | -3.266 | -13.125 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | ▲60.0% |
| Ebit Margin | -16931.0% | ▲198758.4% | ▲29593.1% |
| Ebitda Margin | -16194.7% | ▲192347.4% | ▲28752.6% |
| Operating Profit Margin | -18477.8% | ▲223201.1% | ▲33553.5% |
| Pretax Profit Margin | -16931.5% | ▲198769.9% | ▲29595.1% |
| Continuous Operations Profit Margin | -16977.8% | ▲197936.7% | ▲29400.6% |
| Net Profit Margin | -7725.2% | ▲72782.7% | ▲9921.4% |
| Bottom Line Profit Margin | -7725.2% | ▲72782.7% | ▲9921.4% |
| Current Ratio | 9.130 | ▼-1.801 | ▼-7.598 |
| Quick Ratio | 9.130 | ▼-1.801 | ▼-7.598 |
| Solvency Ratio | -1.794 | ▼-0.381 | ▲1.466 |
| Cash Ratio | 3.531 | ▲0.794 | ▼-7.559 |
| Price To Earnings Ratio | -4.308 | ▼-1.582 | ▼-0.352 |
| Price To Earnings Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Forward Price To Earnings Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Price To Earnings Diluted Ratio | -4.308 | ▼-1.582 | ▼-0.352 |
| Price To Earnings Diluted Growth Ratio | 0.267 | ▲0.578 | ▲0.717 |
| Price To Book Ratio | -0.297 | ▼-0.130 | ▼-2.453 |
| Price To Sales Ratio | 335.982 | ▼-1841.365 | ▼-166.684 |
| Price To Free Cash Flow Ratio | -2.217 | ▼-1.156 | ▲0.823 |
| Price To Operating Cash Flow Ratio | -2.498 | ▼-1.188 | ▲0.858 |
| Debt To Assets Ratio | 0.012 | ▲0.005 | ▼-0.002 |
| Debt To Equity Ratio | -0.004 | ▼-0.001 | ▼-0.011 |
| Debt To Capital Ratio | -0.004 | ▼-0.001 | ▼-0.011 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | -0.332 | ▲0.112 | ▼-0.305 |
| Working Capital Turnover Ratio | 0.003 | ▲0.003 | ▲0.002 |
| Operating Cash Flow Ratio | -3.907 | ▼-0.418 | ▲0.526 |
| Operating Cash Flow Sales Ratio | -134.510 | ▲1528.004 | ▲224.895 |
| Free Cash Flow Operating Cash Flow Ratio | 1.127 | ▼-0.107 | ▼-0.047 |
| Debt Service Coverage Ratio | -36258.250 | ▼-18714.472 | ▼-23170.035 |
| Interest Coverage Ratio | -41251.750 | ▼-20843.306 | ▼-26252.012 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -29.761 | ▲9.284 | ▲2.050 |
| Capital Expenditure Coverage Ratio | -7.904 | ▼-3.623 | ▲5.349 |
| Dividend Paid And Capex Coverage Ratio | -7.904 | ▼-3.623 | ▲5.349 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.986 | ▼-2.221 | ▲0.750 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $680.9M | $375.5M | $249.3M | $958.1M | $716.5M | |
| Enterprise value | $576.4M | $279.7M | $193.1M | $470.2M | $697.3M | |
| EV / Sales | 645.47x | 3679.70x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.80x | -2.21x | -2.14x | -6.10x | -13.86x | |
| EV / Free cash flow | -4.26x | -1.79x | -1.55x | -5.96x | -12.56x | |
| EV / EBITDA | -3.99x | -1.76x | -1.54x | -3.27x | -13.12x | |
| Net debt / EBITDA | 0.72x | 0.60x | 0.45x | 3.39x | 0.36x | |
| Current ratio | 9.13x | 10.93x | 14.94x | 46.42x | 2.21x | |
| Income quality | 0.79x | 0.77x | 0.67x | 0.52x | 0.91x | |
| Graham net-net | $2 | $3 | $5 | $8 | $0 | |
| Tax burden | 45.6% | 37.3% | 27.4% | 73.4% | 100.1% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.1% | 100.0% | |
| Working capital | $249.9M | $359.7M | $349.1M | $493.8M | $15.0M | |
| Invested capital | $304.8M | $404.9M | $395.5M | $507.1M | $28.0M | |
| Return on assets | -20.6% | -13.9% | -8.4% | -20.9% | -136.8% | |
| Operating ROA | -42.5% | -42.6% | -32.3% | -54.8% | -193.4% | |
| Return on tangible assets | -20.6% | -13.9% | -8.4% | -20.9% | -138.3% | |
| Return on equity | 6.8% | 6.1% | 3.2% | 9.9% | -204.9% | |
| Return on invested capital | -53.9% | -45.1% | -38.2% | -30.1% | -195.1% | |
| Return on capital employed | -54.1% | -45.4% | -38.3% | -30.2% | -196.9% | |
| Earnings yield | -23.0% | -37.0% | -32.3% | -25.6% | -17.5% | |
| Free cash flow yield | -45.1% | -94.2% | -113.1% | -18.7% | -17.6% | |
| Capex / Op. cash flow | -12.7% | -23.4% | -38.0% | -2.4% | -10.3% | |
| Capex / Depreciation | 231.1% | 543.2% | 887.5% | 60.8% | 261.7% | |
| Capex / Sales | 1701.7% | 38827.6% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 5798.1% | 73794.7% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 12779.7% | 167984.2% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 2837.2% | 38647.4% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | |
| Days sales outstanding | 461d | 11752d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 461d | 11752d | 0d | 0d | 0d | |
| Cash conversion cycle | 461d | 11752d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-14 ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK''s cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising ''going concern'' doubts.
- 2026-08-10 ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.
- 2026-06-02 ProKidney Appoints Kenneth Locke as Chief Technical Officer Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel